ROUTE    CONTACT
zoeken
FOLLOW US:
Medical Need
Medical Need

Traditional risk factors such as cholesterol and high blood pressure are insufficient to adequately assess the risk for cardiovascular events, while the search for new biomarkers especially in the field of secondary prevention is rather unexplored. Hence, a high need exists for diagnostic tests identifying high-risk populations.

Bookmark and Share

The numbers

Despite current risk prediction models and effective therapies, cardiovascular disease (CVD) remains the number one killer of the aging population in Western society*. In addition, cardiovascular morbidity is rapidly increasing in developing countries*. Worldwide about 17 million deaths each year are caused by cardiovascular disease and the costs for health care and loss of productivity exceed €169 billion a year in Europe. In the United States alone cardiovascular diseases are responsible for causing approximately 40% of all deaths and for a major economic burden with direct annual medical costs of $229 billion.

Atherosclerosis

The underlying cause of cardiovascular disease is atherosclerosis, an inflammatory disease of the arteries that develops over decades and is characterized by thickening of the artery wall due to accumulation of cholesterol. Cardiovascular morbidity and mortality rates continue to increase with the ongoing epidemics of diabetes and obesity.

Cholesterol and smoking are among the traditional markers used to predict the risk for primary cardiovascular events. Current risk prediction models based on these risk factors were developed for patients without clinically manifest cardiovascular disease and are not intended to assess the risk for secondary cardiovascular events.

CAVΛDIS™ biomarkers

CAVΛDIS™ meets that medical need by developing immunoassays based on a series of novel biomarkers with predictive power for cardiovascular events. These markers are over-represented in biological pathways of atherosclerosis and may also have potential as surrogate marker of safety and efficacy in clinical trials and as therapeutic target in drug development.

References

*. Mathers CD, et al. "Projections of global mortality and burden of disease from 2002 to 2030." PLoS Medicine 2006. PubMed ID: 17132052.

  • Worldwide around 17 million people per year die from cardiovascular disease and in US alone 40% of all deaths are caused by CVD.
  • All together atherosclerosis related health care costs in the US and Europe exceed €350 billion per year.
  • The American Heart Association aims at a 25% decrease in risk on coronary heart disease and stroke.
Related items
Our mission
CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. The company's mission is to identify patients at risk of developing heart attacks and strokes. Our ultimate goal is to develop clinically meaningful risk stratification tools that will help personalize treatment and achieve better patient outcomes.
read more
Press Releases
Get up to date with the latest press releases from CAVΛDIS™.

read more